1.Chugh S S，Havmoeller R，Narayanan K，et al. Worldwide epidemiology of atrial fibrillation：a Global Burden of Disease 2010 Study［J］. Circu-lation，2014，129（8）：837-847.

2.Glotzer T V，Ziegler P D. Cryptogenic stroke：Is silent atrial fibril-lation the culprit［J］? Heart Rhythm the Official Journal of the Heart Rhythm Society，2015，12（1）：234-241.

3.Kirchhof P，Benussi S，Kotecha D，et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS［J］. Kardiol Pol，2016，74（12）：1359-1469.

4.Apostolakis S，Sullivan R M，Olshansky B，et al. Factors affecting quality of anticoagulation control among patients with atrial fibril-lation on warfarin：the SAMe-TT ₂R ₂ score［J］. Chest，2013，144（5）：1555-1563.

5.Roldán V，Cancio S，Gálvez J，et al. The SAMe-TT ₂R ₂ Score Predicts Poor Anticoagulation Control in AF Patients：A Prospective ‘Real-world’Inception Cohort Study［J］. American Journal of Medicine，2015，128（11）：1237-1243.

6.Gallego P，Roldan V，Marín F，et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation［J］. Thrombosis & Haemostasis，2013，110（6）：1189-1198.

7.National Clinical Guideline C，National Institute for Health and Clinical Excellence：Guidance，in Atrial Fibrillation：The Management of Atrial Fibrillation. 2014，National Institute for Health and Care Excellence（UK）Copyright（c）National Clinical Guideline Centre，2014，London.

8.Shaw K，Amstutz U，Kim R B，et al. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy［J］. Therapeutic Drug Monitoring，2015，37（4）：428-436.

9.AAOM Clinical Practice Statement：Subject：Management of Patients on Warfarin Therapy［J］. Oral Surg Oral Med Oral Pathol Oral Radiol，2016，122（6）：702-704.

10.Kirkpatrick A W，Roberts D J，Waele J D，et al. Intra-abdominal hyper-tension and the abdominal compartment syndrome：updated consensus defini-tions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome［J］. Intensive Care Medicine，2013，39（7）：1190-1206.

11.Heaton D C，Han D Y，Inder A. Minidose（1mg）warfarin as prophylaxis for central vein catheter thrombosis［J］.Internal Medicine Jounal，2002，32（3）：84-88.

12.Couban S，Goodyear M，Burnell M，et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer［J］. J Clin Oncol，2005，23（18）：4063-4069.

13.AM Y，LJ B，G B，et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters（WARP）：an open-label randomised trial［J］. Lancet，2009，373（9663）：567-574.

14.Rooden C J，Tesselaar M E，Osanto S，et al. Deep vein thrombosis associated with central venous catheters - a review［J］. J Thromb Haemost，2005，3（11）：2409-2419.

15.Geerts W. Central venous catheter-related thrombosis［J］. Hematology Am Soc Hematol Educ Program，2014，2014（1）：306-311.

16.NCCN clinical practice guidelines in Oncology：Cancer-Associated Venous Thromboembolic Disease，2017.

17.You J J，Singer D E，Howard P A，et al. Antithrombotic therapy for atrial fibrillation：Antithrombotic Therapy and Prevention of Thrombosis，9th ed：American College of Chest Physicians Evidence-Based Clinical Practice Guidelines［J］. Chest，2012，141（2 Suppl）：e531S-e575S.

18.Glassock R J，Winearls C. Ageing and the glomerular filtration rate：truths and consequences［J］. Trans Am Clin Climatol Assoc，2009，120（120）：419-428.